|
WaveSense Releases Research Products for
Melanoma Cells - Expands XRC™ Portfolio
March 7, 2006
Extending its position in the field of cellular
analysis, WaveSense recently announced the availability of
the EpiSep™ Melanoma (9.2.27) detection kit. The Melanoma
kit utilizes WaveSense’s proprietary Xenographic Retention
Chromatography™ (XRC™) technology, and a combination
of four antibodies. EpiSep XRC™ is an open platform
for rapid and sensitive capture and sorting of live cells,
proteins, and genes for interrogation – providing ideal
laboratory processes for end-users of the Melanoma kit.
The kit antibodies include; Monoclonal 9.2.27
for recognition of Melanoma-associated Chondroitin Sulfate
Proteogylcan (MCSP) complex for capture on magnetic particles;
and three biotin labeled monoclonal antibodies – M2-7C10,
A103, and T311, which are used to detect and recognize, respectively,
the Mart-1, Melan-A and Tyrosinase epitopes in melanoma cells.
The combination of antibodies, in conjunction with EpiSep
XRC™, provides excellent specificity and sensitivity
for detection of rare cells in a variety of samples that include
blood, tissue preparation, and cell culture.
The EpiSep XRC platform improves workflow procedures
by seamlessly isolating and characterizing target cells from
large backgrounds in a single device - eliminating cumbersome
and prolonged procedures that include centrifugation, aspiration
or decanting steps. Three-dimensional sampling from tissue
is an additive benefit of the WaveSense platform. With respect
to the Melanoma (9.2.27) XRC™ kit, the 9.2.27 antibody
is directed against the 250 KD Melanoma-associated Chondroitin
Sulfate Proteoglycan (MCSP), and then coated onto paramagnetic
particles. The particles capture melanocytes, which are then
simply and easily processed in the EpiSep™ device for
detection and characterization.
WaveSense has collaborated with Drs Oystein
Fodstad and Hanne Kleppe Hoifodt of the Tumor Biology Department
of Radium Hospital in Oslo, Norway to evaluate the utility
of the reagents. In a poster presented at the 2005 Annual
Symposium on Minimal Residual Cancer in San Francisco, CA,
Drs Fodstad and Hoifodt reported that:
“The method allows tumor cells in the
different samples to be identified in less than 2 hours. The
immuno-magnetically captured cells are pure, viable and unaltered
and can be used for further immunological and molecular analysis,
as well as for in vitro and in vivo cell culture.”
WaveSense will showcase its new Melanoma (9.2.27)
XRC™ Kit, April 1-5th, at the 2006 annual meeting of
the American Association of Cancer Research.
WaveSense develops and manufactures novel products
for life science research and clinical research laboratories.
The company’s extensive line of products offer robust
and easy to use assays for a wide variety of life science
research applications. These include rapid and sensitive cell
based assays, rare cell capture and detection, and tumor cell
biomarker characterization. The power of the proprietary XRC™
technology allows use of samples from a variety of sources
such as blood, tissue and bone marrow.
Dr. Oystein Fodstad and Dr. Hanne Kleppe Hoifodt
are affiliated with the Dept. of Tumor Biology, The Norwegian
Radium Hospital in Oslo, Norway. Dr. Fodstad is also with
the University of South Alabama, Cancer Research Institute
in Mobile, AL. Dr.’s Fodstad and Hoifodt are regarded
as world leading authorities in the field of magnetic capture
and isolation of tumor cells. Professor Fodstad has recently
agreed to become Chairman of WaveSense’s Scientific
Advisory Board.
The products described in this announcement
are for research use only and not intended for diagnostic
or therapeutic purposes.
|
